Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -43.12% is 17348% below its 5-year average of 0.25%, near the low end of its 5-year range (-43.12%–86.26%).
As of the fiscal period ended Wednesday, December 31, 2025. 32.09% below its 12-month average of -32.64%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
-43.12%
RETURN ON EQUITY (ROE) AVG TTM
-32.64%
RETURN ON EQUITY (ROE) AVG 3Y
-13.90%
RETURN ON EQUITY (ROE) AVG 5Y
0.25%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-32.09%
CURRENT VS 3Y AVG
-210.27%
CURRENT VS 5Y AVG
-17348.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-495.96%
vs the sector median at left
Moderna, Inc.
Market Cap
$21.45B
Return on Equity (ROE)
-43.12%
TTM Avg
-32.64%
3Y Avg
-13.90%
5Y Avg
0.25%
Market Cap
$20.86B
Return on Equity (ROE)
10.89%
TTM Avg
10.12%
3Y Avg
7.00%
5Y Avg
7.00%
Market Cap
$22.43B
Return on Equity (ROE)
21.82%
TTM Avg
18.68%
3Y Avg
17.25%
5Y Avg
16.03%
Market Cap
$22.59B
Return on Equity (ROE)
-6.79%
TTM Avg
-4.55%
3Y Avg
10.63%
5Y Avg
21.70%
Market Cap
$20.08B
Return on Equity (ROE)
-2.02%
TTM Avg
-13.64%
3Y Avg
-4.29%
5Y Avg
-4.38%
Market Cap
$23.10B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
Market Cap
$23.51B
Return on Equity (ROE)
25.79%
TTM Avg
12.92%
3Y Avg
11.29%
5Y Avg
9.83%
Market Cap
$24.34B
Return on Equity (ROE)
10.79%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$24.42B
Return on Equity (ROE)
2.94%
TTM Avg
29.98%
3Y Avg
64.02%
5Y Avg
111.55%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moderna, Inc. (MRNA) | $21.45B | -43.12% | -32.64% | -13.90% | 0.25% |
| STERIS plc (STE)vs › | $20.86B | 10.89% | 10.12% | 7.00% | 7.00% |
| United Therapeutics Corporation (UTHR)vs › | $22.43B | 21.82% | 18.68% | 17.25% | 16.03% |
| BioNTech SE (BNTX)vs › | $22.59B | -6.79% | -4.55% | 10.63% | 21.70% |
| Viatris Inc. (VTRS)vs › | $20.08B | -2.02% | -13.64% | -4.29% | -4.38% |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.10B | 18.89% | 16.95% | 19.08% | 20.56% |
| Incyte Corporation (INCY)vs › | $23.51B | 25.79% | 12.92% | 11.29% | 9.83% |
| Labcorp Holdings Inc. (LH)vs › | $24.34B | 10.79% | 9.71% | 9.35% | 12.84% |
| Waters Corporation (WAT)vs › | $24.42B | 2.94% | 29.98% | 64.02% | 111.55% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.15B | 18.49% | 13.34% | 14.07% | 18.07% |
ROE
-43.1%
ROA
-27.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -32.62% |
| 2024-12-31 | -32.67% |
| 2023-12-31 | -34.03% |
| 2022-12-31 | 43.73% |
| 2021-12-31 | 86.26% |
| 2020-12-31 | -29.17% |
| 2019-12-31 | -43.75% |
| 2018-12-31 | -25.14% |
| 2017-12-31 | -40.93% |
| 2016-12-31 | -25.68% |
